# Progress Note 06 — Annual Wellness Visit, Subsequent

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Pablo Neruda (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML051-SYN
- Date: 2026-10-05
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marisol Fairweather-Diaz, MD
- Calendar frame: modern shifted

- Visit type: Annual Wellness Visit, Subsequent
- Services: HCPCS G0439 (subsequent annual wellness visit) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Subsequent annual wellness visit; no new complaints. **S**

## History of present illness

Mr. Neruda returns for his subsequent annual wellness visit, with a professional Spanish interpreter; his first was with his previous physician last year. He completed the health risk assessment in Spanish beforehand. He is three weeks past his second leuprolide injection and continues apalutamide; radiotherapy to the prostate finished six weeks ago. The rash has gone. Hot flashes come four or five times a day and wake him once or twice a night; he would rather not take a medicine for them yet. His energy is lower in the afternoons, and he rests after lunch. He has no bone pain, has had no falls, and walks most afternoons. He writes every morning and has kept his official duties, apart from a week of engagements put off during radiotherapy. His interest in sex has fallen, as he was told it might; he has thought about it and does not want treatment for it now. **S**

| Element | Detail |
|---|---|
| Visit | Subsequent annual wellness visit |
| Safety events | No falls, emergency visits or hospital stays in the past year; one sick visit for a drug rash |
| Medicines | Leuprolide 22.5 mg every twelve weeks; apalutamide 240 mg daily; amlodipine 10 mg daily; cholecalciferol 2000 units daily; denosumab 60 mg every six months |
| Active conditions | Metastatic hormone-sensitive prostate cancer on androgen deprivation with apalutamide; hypertension; prediabetes; low bone mass |
| Functional status | Independent in all activities and instrumental activities of daily living |

## Health risk assessment

Completed by the patient before the visit and reviewed during the visit. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Fair to good |
| Psychosocial | Writing every morning; close to his wife and friends; worry about the cancer at times, manageable |
| Tobacco | Never used tobacco |
| Alcohol and drugs | Wine with dinner a few evenings a week (AUDIT-C 2); no other drug use |
| Physical activity | Walks 30 minutes most afternoons; light resistance exercise twice a week, begun for bone and muscle on androgen deprivation |
| Nutrition | Many official dinners; dairy, fish and greens for calcium; weight up 2.2 kg since starting treatment |
| Sleep | Hot flashes wake him once or twice a night; rests after lunch |
| Activities of daily living | Independent |
| Instrumental activities of daily living | Independent; manages his own medicines with a weekly pill box |
| Home safety | Smoke detectors working; rugs secured; good lighting on the stairs |
| Falls | No falls; no fear of falling |
| Hearing and vision | Reading glasses; eye examination last year; hearing good |
| Memory | No concerns |
| Pain | None |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Lower afternoon energy on androgen deprivation; weight up 2.2 kg; no fever or night sweats |
| Eyes | Negative | No change in vision |
| Ears, nose, mouth, and throat | Negative | No hearing change; no mouth sores |
| Cardiovascular | Negative | No chest pain, palpitations or leg swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | Bowels back to normal after radiotherapy; no bleeding |
| Genitourinary | Positive | Nocturia once; stream better; lower libido and erections |
| Musculoskeletal | Negative | No bone or joint pain |
| Integumentary | Negative | Rash resolved |
| Neurological | Negative | No weakness, numbness or unsteadiness |
| Psychiatric | Negative | Mood steady; PHQ-2 score 0 |
| Endocrine | Positive | Hot flashes four or five times a day; no breast tenderness |

12 systems reviewed. **S**

## Current medications

- Amlodipine 10 mg oral tablet, one tablet daily **S**
- Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without food **S**
- Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, every twelve weeks **S**
- Cholecalciferol (vitamin D3) 2000 units (0.05 mg) oral tablet, one tablet daily **S**
- Denosumab 60 mg/mL prefilled syringe, 60 mg subcutaneously every six months, for high fracture risk on androgen deprivation **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/78 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 94.6 kg; BMI 29.9 kg/m². All vital signs are synthetic.

PHQ-2: 0; Mini-Cog: 5; AUDIT-C: 2. All results are synthetic.

## Immunizations given today

- High-dose influenza vaccine, this season **S**
- COVID-19 vaccine, mRNA, this season **S**
- Pneumococcal conjugate vaccine PCV20 **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well and engaged; weight 94.6 kg, BMI 29.9; blood pressure 128/78 |
| Eyes | Near vision 20/30 with reading glasses |
| Ears | Whispered-voice test passed on both sides |
| Neck | No thyroid enlargement; no lymph nodes |
| Cardiovascular | Regular rhythm at 70 per minute; no murmur; no ankle swelling |
| Respiratory | Clear |
| Chest | Mild gynecomastia without tenderness |
| Abdomen | Soft and non-tender |
| Musculoskeletal | No spinal or pelvic tenderness; Timed Up and Go 9 seconds; rises from a chair without using his arms |
| Neurological | Strength and sensation normal in the legs; gait steady; Mini-Cog 5 of 5 |
| Psychiatric | Euthymic, thoughtful; judgment and insight intact |
| Skin | Rash resolved without scarring; no suspicious lesions |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Subsequent annual wellness visit completed**. Health risk assessment reviewed and a written prevention plan given in Spanish. Depression, alcohol, cognitive and fall-risk screens are negative. On the lipid panel from the first visit (total cholesterol 214, HDL 46, LDL 140 mg/dL), with treated blood pressure and no smoking or diabetes, the 10-year ASCVD risk by the pooled cohort equations is about 17 percent; androgen deprivation adds cardiometabolic risk. **S**
   - Atorvastatin 20 mg daily after shared decision; lipid panel and ALT in six weeks, with the TSH and free T4 repeat.
   - Next annual wellness visit in one year.
2. **Androgen deprivation with apalutamide** (Z79.899). Hot flashes, afternoon fatigue, weight gain of 2.2 kg and lower libido, all expected; mild gynecomastia; no falls; cognition normal. **S**
   - Keep walking and resistance exercise, which help fatigue, weight, muscle and bone.
   - Venlafaxine or gabapentin are available for hot flashes if he wants them.
   - Sexual health: the cancer center's sexual health clinic is open to him, alone or with his wife, whenever he wishes.
3. **Hypertension** (I10). 128/78 mm Hg on amlodipine 10 mg; at goal. **S**
   - Continue amlodipine 10 mg daily.

## Medication changes

- Started: Atorvastatin 20 mg oral tablet, one tablet daily **S**

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Influenza vaccine | Completed today | High-dose vaccine given today |
| COVID-19 vaccine | Completed today | This season's vaccine given today |
| Pneumococcal vaccine | Completed today | PCV20 given today; no earlier pneumococcal vaccine; no further doses needed |
| Recombinant zoster vaccine | Due | Never given; dose 1 at the next visit, as he wanted no more than three injections today |
| RSV vaccine | Not indicated | Under 75 without a chronic heart, lung, kidney or immune condition that raises his risk; to be reviewed at 75 or if that changes |
| Tetanus, diphtheria and pertussis booster | Up to date | Tdap six years ago; next in four years |
| Colorectal cancer screening | Up to date | Normal colonoscopy seven years ago; next due in three years |
| Abdominal aortic aneurysm screening | Not indicated | Recommended for men 65 to 75 who have ever smoked; he never smoked |
| Lung cancer screening | Not indicated | Never smoker |
| Hepatitis C screening | Up to date | One-time screening negative eight years ago |
| Cholesterol and statin decision | Completed today | 10-year ASCVD risk about 17 percent; atorvastatin 20 mg started after discussion |
| Diabetes screening | Up to date | Hemoglobin A1c 6.1 percent three weeks ago (prediabetes); repeat yearly on androgen deprivation |
| Bone density | Up to date | DXA four months ago; denosumab every six months; repeat DXA in one to two years |
| Depression screening | Completed today | PHQ-2 score 0 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C score 2, low risk |
| Cognitive assessment | Completed today | Mini-Cog 5 of 5 |
| Falls prevention | Completed today | Timed Up and Go 9 seconds; no falls; apalutamide raises fall risk, so resistance and balance exercise continue |
| Skin check | Completed today | No suspicious lesions |

## Advance care planning

Voluntary advance care planning discussion of about 30 minutes, in Spanish with a professional interpreter, with his consent. He named a health care agent, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. He said that what matters most to him is to keep writing, to be told the truth about his illness in his own language, and to make his own decisions. He chose not to record specific treatment preferences today and will review the plan with his oncologist and with this clinic yearly or if his health changes. **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026), Aether Forge
- Medicare Wellness Visits (Medicare Learning Network) (2026), Centers for Medicare & Medicaid Services
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Zoster vaccine dose 1 and blood pressure check in six weeks, with a lipid panel, ALT, TSH and free T4. Medical oncology and the next leuprolide injection in nine weeks. Next annual wellness visit in one year. **S**

